Showing 3661-3670 of 6977 results for "".
- Psoriasis Linked with Education, Mood Disorders: Studyhttps://practicaldermatology.com/news/psoriasis-tied-education-and-mood-disorders-study/2468759/A new genetic study has identified six previously unreported loci associated with psoriasis, emphasizing its genetic complexity and links to socioeconomic and mental health factors. The analysis included data from 925,649 individuals across the FinnGen, Estonian Biobank, and UK Biobank, ma
- Upadacitinib Effective in Adolescents With AD Through 76 Weekshttps://practicaldermatology.com/news/upadacitinib-effective-adolescents-ad-through-76-weeks/2468724/Long-term treatment of adolescents with moderate-to-severe atopic dermatitis (AD) with upadacitinib demonstrated a favorable benefit-risk profile, with sustained efficacy responses through 76 weeks, in a study published in JAMA Dermatology. “Upadacitinib in Adolescents With Moderate to Sev
- Study: Cutaneous Lupus Linked With Elevated Cardiovascular Disease Riskhttps://practicaldermatology.com/news/study-cutaneous-lupus-linked-elevated-cardiovascular-disease-risk/2468723/Patients with cutaneous lupus erythematosus (CLE) face an elevated risk of atherosclerotic cardiovascular disease (ASCVD), comparable to that seen in systemic lupus erythematosus (SLE), according to a new study. Authors of the retrospective cohort study analyzed health records of 8,138 pat
- Early-Onset AD Linked to Higher Rates of Atopic Marchhttps://practicaldermatology.com/news/early-onset-ad-linked-higher-rates-atopic-march/2468704/Early-onset atopic dermatitis (AD) is associated with higher rates of developing atopic march conditions compared to controls, according to new research in the Journal of the American Academy of Dermatology. “Particular attention should be paid towards risk factors and atopic marc
- Mohs Surgery as Effective as Wide Excision for Lentigo Maligna Melanoma: Studyhttps://practicaldermatology.com/news/mohs-surgery-effective-wide-excision-lentigo-maligna-melanoma-study/2468603/New research suggests Mohs micrographic surgery (MMS) may be as effective as wide local excision (WLE) in treating lentigo maligna (LM) and lentigo maligna melanoma (LMM), without compromising melanoma-specific survival rates. Lentigo maligna, often found on sun-damaged skin in older patie
- Roflumilast Cream 0.15% Receives Glamour's Best Eczema Product Award for 2024https://practicaldermatology.com/news/roflumilast-cream-015-receives-glamours-best-eczema-product-award-2024/2468585/Arcutis Biotherapeutics announced today that ZORYVE® (roflumilast) cream 0.15% has been named Best Eczema Product by Glamour magazine in its 2024 Health and Wellness Awards. The cream, which is the first once-daily FDA-approved topical treatment specifically indicated for mild to
- FDA Approves Emrosi for Rosaceahttps://practicaldermatology.com/news/fda-approves-emrosi-rosacea-treatment/2468543/The US Food and Drug Administration (FDA) has approved Emrosi™ (Minocycline Hydrochloride Extended Release Capsules, 40 mg) as a treatment for inflammatory lesions of rosacea in adults. According to a press release from the manufacturer, Journey Medical (in partnership with Dr.
- ImmunoSkin Conference Explores Inflammatory Skin Conditionshttps://practicaldermatology.com/news/immunoskin-conference-explores-inflammatory-skin-conditions/2468494/The third annual ImmunoSkin conference was held October 26-27 in Barcelona, Spain, highlighting new therapeutic strategies and facilitating exchange about the biological mechanisms of psoriasis and atopic dermatitis through clinical case studies and expert debates. The event was hosted by
- ECZTEND: Tralokinumab-ldrm Achieves Lasting Efficacy in AD Patientshttps://practicaldermatology.com/news/ecztend-tralokinumab-ldrm-achieves-lasting-efficacy-ad-patients/2468493/Final results presented at Fall Clinical 2024 from the ECZTEND study confirmed long-term safety and efficacy of tralokinumab-ldrm in adolescents and adults with moderate-to-severe atopic dermatitis (AD). The open-label, single-arm trial included 1,672 participants who transitioned from nin
- Deuruxolitinib Shows Efficacy in Adults with Severe Alopecia Areatahttps://practicaldermatology.com/news/deuruxolitinib-shows-efficacy-adults-severe-alopecia-areata/2468485/New findings on LEQSELVI™ (deuruxolitinib) presented at the 44th Annual Fall Clinical Dermatology Conference showed sustained efficacy and safety in adults with severe alopecia areata (AA). According to a press release from the manufacturer, the FDA-approved JAK inhibitor showed meaningfu